Taking Aim at Obesity: Strategies for Effective and Equitable Management in Primary Care Practice
Released On
July 31, 2025
Expires On
July 31, 2026
Media Type
Internet
Completion Time
90 minutes
Specialty
Primary Care
Topic(s)
Obesity
Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Novo Nordisk, Inc.
Credit Available
- Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is designed for US-based primary care providers including community-based providers such as those practicing in ACOs, FQHCs, and rural-based practices.
Program Overview
Obesity is a chronic, progressive, and relapsing disease associated with increased risks of cardiovascular disease, type 2 diabetes, dyslipidemia, hypertension, and other serious health complications. In the United States, approximately 40% of adults have obesity and although expert guidelines offer recommendations for optimal management of patients with overweight and obesity, gaps persist. The variables contributing to this are multifactorial, hindering long-term management and leading to undertreatment.
These challenges are further amplified for patients being treated in primary care settings and community health centers that provide care to the most high-risk and underinsured patients in the United States. These providers face increased workloads, financial challenges, and provider burnout, which can further exacerbate inequities in care access.
To support primary care providers in efficiently and effectively improving evidence-based obesity management for all patients, this practice guide synthesizes strategies tested in a real-world setting and frames educational and practical content in an adaptable and sustainable manner so learners can easily model best practices in their own clinical setting.
Learning Objectives
Upon completion of this activity, learners will be able to:
- Explain the rationale for prioritizing obesity management to improve cardiometabolic outcomes
- Individualize obesity treatment strategies based on latest evidence for weight reduction and cardiometabolic outcomes
- Integrate training and operational frameworks to provide comprehensive, long-term patient care in the primary care setting
- Implement shared decision-making strategies to engage patients and families in discussions around weight management goals, preferences, values, and concerns
Faculty
Scott Kahan, MD, MPH
Director, National Center for Weight and Wellness
Faculty, George Washington University School of Medicine
Washington, DC
Silvana Pannain, MD
Associate Professor,
University of Chicago Medical Center
Director of Chicago Weight Center for Weight and Metabolic Health
University of Chicago Medicine
Chicago, IL
Accreditation Statement
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
Disclosures of Conflicts of Interest
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
The following financial relationships have been provided:
Scott Kahan, MD, MPH
Consultant: Boehringer Ingelheim, Currax, Lilly, Novo Nordisk
Silvana Pannain, MD
Speaker: Lilly, Novo Nordisk
Research Support: Amgen, Novo Nordisk, Strecture Therapeutics
Stock Ownership (publicly-traded): Lilly, Novo Nordisk
The University of Chicago Pritzker School of Medicine, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 90 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, XX % must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Disclosure of Unlabeled Use:
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: Phentermine is not approved for long-term weight management. GLP-1 agonists other than liraglutide and semaglutide, pramlintide, SGLT2 inhibitors, zonisamide, metformin, topiramate (as monotherapy), oral semaglutide, orforglipron, cagrisema, survodutide, and retatrutide are not approved for weight management.
Disclaimer
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and The University of Chicago requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information
For CME questions, contact Laurie Novoryta at [email protected].